Structure and function of the 5HT2A/mGluR2 complex in schizophrenia

$402,732R01FY2013MHNIH

Icahn School Of Medicine At Mount Sinai, New York NY

Investigators

Linked publications, trials & patents

Paper 38648100 Paper 38561467 Paper 37759040 Paper 37537185 Paper 37461593 Paper 37352762 Paper 37293095 Paper 36889432 Paper 36100039 Paper 35963476 Paper 35900876 Paper 35681029 Paper 35183539 Paper 34887589 Paper 34741320 Paper 34686347 Paper 34480967 Paper 34345931 Paper 33539816 Paper 33485732 Paper 33400504 Paper 33082287 Paper 32861513 Paper 32726588 Paper 32170216 Paper 31987863 Paper 31954738 Paper 31582824 Paper 31536718 Paper 31460790 Paper 31220352 Paper 30807107 Paper 30609893 Paper 30209534 Paper 30099006 Paper 30038413 Paper 30025863 Paper 29963329 Paper 28783139 Paper 28677096 Paper 28265857 Paper 28202291 Paper 28192423 Paper 28154892 Paper 28115742 Paper 27835800 Paper 27501227 Paper 27385190 Paper 26780666 Paper 26758213 Paper 26148747 Paper 26120009 Paper 25734378 Paper 25374032 Paper 25346690 Paper 23745738 Paper 23702798 Paper 23663970 Paper 23508685 Paper 23416703 Paper 23336043 Paper 23333599 Paper 23325246 Paper 23253383 Paper 23176747 Paper 23129762 Paper 22864611 Paper 22842765 Paper 22692564 Paper 22681249 Paper 22118459 Paper 21645528 Paper 21619615 Paper 21289196 Paper 21276828 Paper 20864091 Paper 20632964 Paper 20421895 Paper 19707855

Abstract

DESCRIPTION (provided by applicant): One of the guiding objectives of modern schizophrenia research is to build a bridge from molecular and cellular biology to the clinical symptoms of this psychotic mental disorder. Monoaminergic neurotransmitters have been the principal focus of schizophrenia research for many decades. Several approaches have also linked the neurotransmitter glutamate to the neurochemical alterations in patients with schizophrenia. Notably, clozapine and other atypical antipsychotics have high affinity for serotonin 5-HT2A receptors (2AR), and metabotropic glutamate receptors 2/3 (mGluR2/3) agonists have recently shown efficacy in treating schizophrenia. We identify a novel and unexpected functional brain 2AR/mGluR2 receptor complex that may unify the anti- serotonin and glutamatergic therapies of schizophrenia. Our results based on in vitro, animal models and postmortem human brain of schizophrenic subjects suggest that this 2AR/mGluR2 complex may be responsible for some psychotic symptoms in schizophrenia, and that it is the direct target of these two different classes of antipsychotic drugs. In order to understand the role of the 2AR/mGluR2 complex in brain function and to set the stage for future drug development we will pursue two aims. We will use in vitro studies in conjunction with cutting-edge computational approaches to investigate the molecular determinants at the interaction interface responsible for 2AR/mGluR2 complex stabilization and functional crosstalk. In cortical primary cultures and in vivo in mouse models we will study the neuronal signaling and behavior dependent on 2AR/mGluR2 complex function. Results of the proposed studies have the potential to provide a greater understanding of the structure and function of the 2AR/mGluR2 complex than is currently available for any G protein-coupled receptor heterocomplex, and may provide the basis for new pharmacological approaches to the treatment of schizophrenia.

View original record on NIH RePORTER →